乳腺癌治疗对就业的影响:多中心前瞻性队列研究(CANTO)
该研究基于法国CANTO前瞻性队列,纳入1,874例诊断时在职且≤57岁的I-III期乳腺癌患者,评估诊断后2年未重返工作(non-RTW)的情况。结果显示21%患者未重返工作;含曲妥珠单抗的化疗方案组合、≥3级CTCAE毒性、手臂症状、焦虑和抑郁与non-RTW风险升高相关。研究提示需针对高危患者提供支持性干预以促进重返工作。
要点
- 诊断后2年,21%的乳腺癌患者未重返工作。
- 含曲妥珠单抗的化疗方案组合与non-RTW风险升高相关。
- ≥3级毒性、手臂症状、焦虑和抑郁亦与non-RTW相关。
核心结论
- 接受含曲妥珠单抗的系统治疗组合与未重返工作的 odds 升高相关。
- 报告严重躯体或心理症状的患者失业可能性更高。
研究设计与样本
- 法国前瞻性临床队列(CANTO),纳入1,874例诊断时在职且≤57岁的I-III期乳腺癌女性。
- 结局为诊断后2年未重返工作(non-RTW)。
- 自变量包括治疗特征、诊断后1年采集的CTCAE v4毒性及患者报告结局(EORTC QLQ-BR23、QLQ-FA12、HADS)。
- 采用logistic回归评估non-RTW相关因素,并调整年龄、分期、合并症和社会经济协变量。
主要发现
- 诊断后2年,21%的患者未重返工作。
- 与化疗-内分泌治疗相比,化疗-曲妥珠单抗的non-RTW OR为2.01(95% CI 1.18-3.44),化疗-曲妥珠单抗-内分泌治疗OR为1.62(95% CI 1.10-2.41)。
- ≥3级CTCAE毒性(vs 无)OR为1.59(95% CI 1.15-2.18)。
- 手臂症状(vs 无)OR为1.59(95% CI 1.19-2.13)。
- 焦虑(vs 无)OR为1.47(95% CI 1.02-2.11),抑郁(vs 无)OR为2.29(95% CI 1.34-3.91)。
临床怎么用
- 对接受含曲妥珠单抗方案、出现≥3级毒性、手臂症状或焦虑抑郁的患者,应关注其重返工作风险。
- 可考虑针对高危患者提供支持性干预以促进重返工作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Adverse effects of breast cancer treatment can negatively affect survivors' work ability. Previous reports lacked detailed clinical data or health-related patient-reported outcomes (PROs) and did not prospectively assess the combined impact of treatment and related sequelae on employment. METHODS: We used a French prospective clinical cohort of patients with stage I-III breast cancer including 1,874 women who were working and ≥ 5 years younger than legal retirement age (≤ 57 years) at breast cancer diagnosis. Our outcome was nonreturn to work (non-RTW) 2 years after diagnosis. Independent variables included treatment characteristics as well as toxicities (Common Toxicity Criteria Adverse Events [CTCAE] v4) and PROs (European Organization for Research and Treatment of Cancer [EORTC] Quality of life Questionnaires, Breast cancer module [QLQ-BR23] and Fatigue module [QLQ-FA12], Hospital Anxiety and Depression Scale) collected 1 year after diagnosis. Logistic regression models assessed correlates of non-RTW, adjusting for age, stage, comorbidities, and socioeconomic covariates. RESULTS: Two years after diagnosis, 21% of patients had not returned to work. Odds of non-RTW were significantly increased among patients treated with combinations of chemotherapy and trastuzumab (odds ratio [OR] v chemotherapy-hormonotherapy: for chemotherapy-trastuzumab, 2.01; 95% CI, 1.18 to 3.44; for chemotherapy-trastuzumab-hormonotherapy, 1.62; 95% CI, 1.10 to 2.41). Other significant associations with non-RTW included grade ≥ 3 CTCAE toxicities (OR v no, 1.59; 95% CI, 1.15 to 2.18), arm morbidity (OR v no, 1.59; 95% CI, 1.19 to 2.13), anxiety (OR v no, 1.47; 95% CI, 1.02 to 2.11), and depression (OR v no, 2.29; 95% CI, 1.34 to 3.91). CONCLUSION: Receipt of systemic therapy combinations including trastuzumab was associated with increased odds of non-RTW. Likelihood of unemployment was also higher among patients who reported severe physical and psychological symptoms. This comprehensive study identifies potentially vulnerable patients and warrants supportive interventional strategies to facilitate their RTW.
引用
- Dumas A, Vaz Luis I, Bovagnet T, et al. Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). J Clin Oncol. 2019. PMID: 31834818. doi:10.1200/JCO.19.01726
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。